NSE: NATCOPHARM | BSE: 524816

Mid-range Performer

Download real time

903.20 25.95 (2.96%)

High volume today

NSE 01 Dec, 2025 3:31 PM (IST)

16,177.2

Market Cap

High in industry

Beta 1Year

Very High Volatility

Natco Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for NATCOPHARM, BSE:524816 Natco Pharma Ltd.

Natco Pharma Ltd.

09 Aug 2018

903.20

2.96%

Natco Pharma Limited

Hold: Natco Pharma Ltd.

ICICI Securities Limited

Revenues grew 25.8% YoY to | 538.6 crore (I-direct estimate: | 659.6 crore) due to windfall from limited competition products (Glatiramer Acetate, Liposomal Doxorubicin and Lanthanum Carbonate) in US EBITDA margins improved 847 bps YoY to 40.4% (I-direct estimate: 50.1%) mainly due to better realisation from limited competition launches in the US. However, it was below I-direct estimates mainly due to higher employee cost and other expenditure Net profit grew 93.2% YoY to | 181.6 crore (I-direct estimate: | 248.5...

ICICI Securities Limited downgraded Natco Pharma Ltd. to Sell with a price target of 750.0 on 15 Nov, 2025.

Natco Pharma Ltd.

24 May 2018

903.20

2.96%

Natco Pharma Limited

Hold: Natco Pharma Ltd.

Recommendation Target

ICICI Securities Limited

EBITDA margins improved 723 bps YoY to 50% (I-direct estimate: 57.6%) mainly due to better realisation from limited competition launches in the US. However, it was below I-direct estimates mainly due to lower gross margins (84% vs. I-direct estimate of 90%) Adjusted net profit increased 69.7% YoY to | 300 crore (I-direct...

Number of FII/FPI investors decreased from 317 to 235 in Sep 2025 qtr

Natco Pharma Ltd.

09 Apr 2018

903.20

2.96%

Natco Pharma

Buy: Natco Pharma Ltd.

Geojit BNP Paribas

NATCO Pharma (NATCO) is a R&D; focussed, vertically integrated pharmaceutical company with an experienced management team and presence across multiple speciality therapeutic segments. High emphasis on R&D; and complex molecules focusing on long...

Number of FII/FPI investors decreased from 317 to 235 in Sep 2025 qtr

Natco Pharma Ltd.

14 Feb 2018

903.20

2.96%

Result Update:Natco Pharma

Buy: Natco Pharma Ltd.

Target

Axis Direct

Q3 sales were 16% below expectations on weak India business (down 24% YoY on weak Hep-C sales) and lower-than-expected market share in gCopaxone 40mg (14-15%). However, gross margin was strong at 88% (up 18.6 pp YoY)

ICICI Securities Limited downgraded Natco Pharma Ltd. to Sell with a price target of 750.0 on 15 Nov, 2025.

Natco Pharma Ltd.

09 Feb 2018

903.20

2.96%

Natco Pharma Ltd Q3FY18 results comment

Results Update: Natco Pharma Ltd.

HDFC Securities

Natco Pharma Ltd Q3FY18 results comment Revenue grew by 31.76% to Rs. 562.2 Cr in Q3FY18 when compared to the previous quarter. On the other hand, it decreased by 16.08% when compared with Q3FY17.

Natco Pharma Ltd. is trading above all available SMAs

Natco Pharma Ltd.

11 Dec 2017

903.20

2.96%

Natco Pharma Ltd: Limited Competition Specialty Generics in ... (Dec 11, 2017)

Buy: Natco Pharma Ltd.

Target

Karvy

gCopaxone and gTamiflu Provide Significant Opportunity: Natco's partner Mylan launched gCopaxone both 20mg and 40mg. All patents expired for 20mg but 40mg patent litigation is ongoing, thus 40mg is an at-risk launch. The 40mgversion is protected by 5 orange book patents, claims of 4 of these patents were held invalid by District Court and litigation of the fifth patent issued in Aug 2016 was dismissed with prejudice.

Natco Pharma Ltd. is trading at high day volume of 5.2M.

Natco Pharma Ltd.

09 Nov 2017

903.20

2.96%

Result Update:Natco Pharma

Buy: Natco Pharma Ltd.

Target

Axis Direct

Though Q2 revenue declined 9% YoY (on a high base), EBITDA and PAT grew 16% and 27% led by higher-margin limited-competition product gDoxil in US. We expect strong PAT growth of 113% in H2 driven by gCopaxone, gDoxil, gTamiflu OS.

ICICI Securities Limited downgraded Natco Pharma Ltd. to Sell with a price target of 750.0 on 15 Nov, 2025.

Natco Pharma Ltd.

06 Nov 2017

903.20

2.96%

Natco Pharma Limited

Buy: Natco Pharma Ltd.

Recommendation Target

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues declined 7% YoY to | 427 crore (I-direct estimate: | 496 crore). The revenues were lower than I-direct estimates mainly due to increase in competition in Hep C sales EBITDA margins improved 580 bps YoY to 28.6% (I-direct estimate: 31%) mainly due to a favourable product mix. EBITDA grew 16% to | 122 crore (I-direct estimate: | 154 crore) Adjusted net profit increased 28% YoY to | 85 crore (I-direct...

Natco Pharma Ltd. has an average target of 845.00 from 2 brokers.

Natco Pharma Ltd.

06 Nov 2017

903.20

2.96%

Natco Pharmaceuticals Limited - Result Update Q2FY18

Hold: Natco Pharma Ltd.

Recommendation Target

Edelweiss

Natco Pharmaceuticals Limited (NATCO) Q2FY18: Underperformance led by pricing pressure across; exciting launches ahead.

Natco Pharma Ltd. is trading above all available SMAs

Natco Pharma Ltd.

16 Oct 2017

903.20

2.96%

Company Update:Natco Pharma

Buy: Natco Pharma Ltd.

Axis Direct

Natco's (partner Mylan) 1st generic approval for gCopaxone 40mg (USD 2.9 bn market; possibility of 180 day exclusivity) and 2nd generic approval for gCopaxone 20mg (USD 700 mn market) demonstrate its R&D; ability to execute on complex generics with intricate chemistry and complex processes

Natco Pharma Ltd. has an average target of 845.00 from 2 brokers.

Is Natco Pharma Ltd. worth buying?

593 Votes:

Buy 82.97%

Sell 7.42%

Hold 9.61%

RESEARCH REPORTS

Sell SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf